Compare DFIN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | SVRA |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 991.6M | 1.1B |
| IPO Year | 2017 | 2009 |
| Metric | DFIN | SVRA |
|---|---|---|
| Price | $39.77 | $5.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $61.50 | $7.33 |
| AVG Volume (30 Days) | 310.8K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $963,000,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $3.87 | $430.87 |
| P/E Ratio | $30.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.07 | $1.98 |
| 52 Week High | $66.25 | $7.01 |
| Indicator | DFIN | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 56.50 |
| Support Level | $37.11 | $4.78 |
| Resistance Level | $50.68 | $5.43 |
| Average True Range (ATR) | 1.45 | 0.26 |
| MACD | 0.34 | 0.04 |
| Stochastic Oscillator | 64.37 | 93.88 |
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).